Cardiovascular disorders therapy - TransTech Pharma
Latest Information Update: 23 Sep 2010
At a glance
- Originator TransTech Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 23 Sep 2010 Discontinued - Phase-I for Cardiovascular disorders in USA (unspecified route)
- 23 Mar 2005 Phase-I clinical trials in Cardiovascular disorders in USA (unspecified route)
- 19 Jul 2004 Preclinical trials in Cardiovascular disorders in USA (unspecified route)